3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Status
Completed
4
Active not recruiting
3
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Breast
2
Thoracic
1
Gynecologic
1
Conditions
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
30
Cisplatin
20
Carboplatin
20
Paclitaxel
18
Dexamethasone
15
Pemetrexed
13
Nivolumab
13
Ipilimumab
12
Fluorouracil
11
Cyclophosphamide
11
Gemcitabine
10
Trastuzumab
9
Docetaxel
9
Cytarabine
9
daratumumab
8
atezolizumab
8
Rituximab
8
Capecitabine
8
Lenalidomide
7
Doxorubicin
7
zanubrutinib
6
Prednisone
6
Daunorubicin
6
Bortezomib
6
venetoclax
5
trametinib
5
nilotinib
5
ibrutinib
5
fludarabine
5
dabrafenib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Completed
×
Has announcements
×
Vinorelbine
×
Clear all
NCT04697628
2026-02-24
innovaTV 301
Seagen Inc.
Phase 3
Completed
502 enrolled
18 charts
1 FDA
NCT02998528
2026-01-06
CheckMate 816
Bristol-Myers Squibb
Phase 3
Completed
505 enrolled
17 charts
1 FDA
NCT03901339
2024-10-21
TROPiCS-02
Gilead Sciences
Phase 3
Completed
543 enrolled
25 charts
1 FDA
NCT02574455
2022-06-15
ASCENT
Gilead Sciences
Phase 3
Completed
529 enrolled
23 charts
1 FDA